Retinal Edema Pipeline Analysis Report 2026

Retinal edema is characterized by fluid accumulation within the retinal layers, resulting in swelling and progressive vision impairment. According to Özlem Candan et al., 2025, macular edema affects slightly more than half of individuals with retinal vein occlusion, accounting for approximately 52.5% of cases, with a 95% confidence interval ranging from 47.48% to 57.56%. According to the retinal edema pipeline analysis, the pipeline is advancing with multiple candidates across early- and late-stage development. Current therapies include anti-VEGF agents, corticosteroids, and sustained-release delivery systems. The increasing emphasis on targeted biologics, innovative drug delivery technologies, and the rising retinal disorder incidence is expected to support robust pipeline growth in the coming years.

Report Coverage

The Retinal Edema Pipeline Analysis Report gives comprehensive insights into retinal edema therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for retinal edema. The retinal edema report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The retinal edema pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with retinal edema treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to retinal edema.

Retinal Edema Pipeline Outlook

Retinal edema is a condition characterized by fluid accumulation in the retina, often caused by retinal vein occlusion, diabetic retinopathy, or inflammation. The excess fluid leads to swelling, impaired vision, and distortion of the retinal structure, potentially resulting in vision loss if untreated. It occurs when the blood-retinal barriers are compromised, allowing leakage of fluids and proteins into the retinal tissue.

Retinal edema treatments include anti-vascular endothelial growth factor injections, corticosteroid therapies, and laser photocoagulation. These interventions aim to reduce retinal swelling, improve visual acuity, and prevent disease progression, with dosing schedules tailored to individual patient response and severity. In November 2025, Regeneron’s EYLEA HD 8 mg injection demonstrated strong efficacy in the retinal edema pipeline landscape, showing non-inferior visual acuity gains and reduced injection frequency in patients with retinal vein occlusion, as confirmed in the phase 3 QUASAR trial.

Retinal Edema Epidemiology

The pipeline shows significant growth potential due to the rising burden of diabetic eye disease. According to Özlem Candan et al., 2025, macular edema affects 52.52% of patients with retinal vein occlusion. According to Genentech, diabetic macular edema impacts approximately 29 million people worldwide. According to Yuan, Yuan et al., 2024, diabetic retinopathy accounts for 89.53% of research grants focused on diabetic eye disease, while 58.19% of clinical trials target diabetic macular edema. Despite these efforts, few new drugs have been approved, highlighting an urgent need for innovative therapeutics in retinal edema management.

Retinal Edema - Pipeline Therapeutic Assessment

This section of the report covers the analysis of retinal edema drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The retinal edema pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Retinal Edema Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 31%, covers a major share of the total retinal edema clinical trials, highlighting significant mid-stage development activity that can drive innovation and market expansion. Phase III contributes 26%, supporting late-stage advancements and potential approvals. Phase I holds 21%, early phase I accounts for 10%, and phase IV represents 12%, reflecting ongoing post-marketing studies that enhance treatment optimization and patient outcomes.

Retinal Edema Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the retinal edema pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The retinal edema report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for retinal edema. Anti-vascular endothelial growth factor (VEGF) therapies are leading the retinal edema drug pipeline, targeting abnormal blood vessel growth and leakage in the retina. For instance, Roche’s Vabysmo® (faricimab) is a bispecific antibody inhibiting both angiopoietin-2 and VEGF-A pathways, showing sustained vision improvements and retinal drying in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Retinal Edema Clinical Trials - Key Players

The report for the retinal edema pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed retinal edema therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in retinal edema clinical trials:

• Kodiak Sciences Inc.
• Kiora Pharmaceuticals, Inc.
• AbbVie
• Boehringer Ingelheim
• EyeBiotech Ltd.
• Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
• Incepta Pharmaceuticals Ltd.
• Novartis Pharmaceuticals
• AiViva BioPharma, Inc.
• Therini Bio Pty Ltd.
• Outlook Therapeutics, Inc.

Retinal Edema - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for retinal edema. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of retinal edema drug candidates.

Drug: KSI-101

KSI-101 (Tabirafusp Alfa) is a novel, high-strength (100 mg/mL) bispecific protein that targets interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), key mediators of inflammation and vascular leakage in retinal disease. Sponsored by Kodiak Sciences Inc, this randomized, double-masked, sham-controlled Phase 3 PINNACLE study is evaluating the efficacy and safety of intravitreal KSI-101 in patients with macular edema secondary to inflammation (MESI). The drug is being administered via intravitreal injection to reduce retinal fluid and improve visual outcomes. Primary completion is estimated in December 2026, with overall study completion anticipated in July 2027.

Drug: KIO-104

KIO-104 is a potent, locally delivered small molecule designed to treat inflammatory retinal diseases, including macular edema. Administered via intravitreal injection, KIO-104 works by inhibiting the mitochondrial enzyme DHODH, reducing T-cell replication, and suppressing pro-inflammatory cytokines that drive retinal damage. The Phase 2 KLARITY-1 study, sponsored by Kiora Pharmaceuticals, Inc., is assessing the safety, tolerability, and efficacy of multiple KIO-104 doses in the study eye, with dosing intervals every 2 or 4 weeks. Enrollment includes 28 participants, and the study is expected to be completed by December 2026.

Genetic: ABBV-RGX-314

RGX-314 is a novel gene therapy being developed by AbbVie for the treatment of Diabetic Retinopathy (DR) with and without center-involved Diabetic Macular Edema (CI-DME). Administered via a single suprachoroidal space (SCS) injection, RGX-314 uses the NAV® AAV8 vector to deliver an antibody fragment that inhibits vascular endothelial growth factor (VEGF), preventing abnormal blood vessel growth and fluid accumulation in the retina. This Phase II, randomized, dose-escalation study is examining the drug’s safety, tolerability, and efficacy in approximately 139 participants. The study is expected to be completed in December 2026, with participants receiving either RGX-314 or comparator treatments.

Key Questions Answered in the Retinal Edema Pipeline Insight Report

• Which companies/institutions are leading the retinal edema drug development?
• Which company is leading the retinal edema pipeline development activities?
• What is the current retinal edema commercial assessment?
• What are the opportunities and challenges present in the retinal edema pipeline landscape?
• What is the efficacy and safety profile of retinal edema pipeline drugs?
• Which company is conducting major trials for retinal edema drugs?
• Which companies/institutions are involved in retinal edema collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in retinal edema?

Reasons To Buy This Report

The Retinal Edema Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for retinal edema. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into retinal edema collaborations, regulatory environments, and potential growth opportunities.